Terms: = Skin cancer AND NF2, ACN, 4771, ENSG00000186575, P35240, SCH, Merlin, BANF AND Staging
4 results:
1. Sentinel lymph node risk prognostication in primary cutaneous melanoma through tissue-based profiling, potentially redefining the need for sentinel lymph node biopsy.
Kött J; Zimmermann N; Zell T; Rünger A; Heidrich I; Geidel G; Smit DJ; Hansen I; Abeck F; Schadendorf D; Eggermont A; Puig S; Hauschild A; Gebhardt C
Eur J Cancer; 2024 May; 202():113989. PubMed ID: 38518535
[TBL] [Abstract] [Full Text] [Related]
2. Clinical evaluation of the clinicopathologic and gene expression profile (CP-GEP) in patients with melanoma eligible for sentinel lymph node biopsy: A multicenter prospective Dutch study.
Stassen RC; Mulder EEAP; Mooyaart AL; Francken AB; van der Hage J; Aarts MJB; van der Veldt AAM; Verhoef C; Grünhagen DJ
Eur J Surg Oncol; 2023 Dec; 49(12):107249. PubMed ID: 37907016
[TBL] [Abstract] [Full Text] [Related]
3. Using the merlin assay for reducing sentinel lymph node biopsy complications in melanoma: a retrospective cohort study.
Hieken TJ; Sadurní MB; Quattrocchi E; Kobic A; Sominidi-Damodaran S; Dwarkasing JT; Meerstein-Kessel L; Bridges AG; Meves A
Int J Dermatol; 2022 Jul; 61(7):848-854. PubMed ID: 35100440
[TBL] [Abstract] [Full Text] [Related]
4. Tumours of familial origin in the head and neck.
Suárez C; Rodrigo JP; Ferlito A; Cabanillas R; Shaha AR; Rinaldo A
Oral Oncol; 2006 Nov; 42(10):965-78. PubMed ID: 16857415
[TBL] [Abstract] [Full Text] [Related]
